Key Metrics
14.3
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.01 - 0.05
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
10 - 15
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.9
5-Year SI
5-year SI
- 0.88 2-year SI
- 0.9 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Oncology
SJR
- Q1 Oncology
- Q1 Immunology
- Q1 Pharmacology
- Q1 Cancer Research
- Q1 Molecular Medicine
- Q1 Immunology and Allergy
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
2.23
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Topics Covered
- Cancer
- Immunotherapy
- Lung cancer
- Immune checkpoint
- Gene expression
- Progression-free survival
- Melanoma
- Tumor growth
- Overall survival
- Body mass index
- Phagocytosis
- Antigen
- Chemokine
- Toxicity
- Immune effector
- Surgical resection
- Chimeric antigen receptor
- Antitumor immunity
- Lung
- Tumor microenvironment
Journal Specifications
| Overview | |
| Publisher | BMJ PUBLISHING GROUP |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2885 |
| Publication Time | 18 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Society for Immunotherapy of Cancer |
| Frequency | Continuous publication |
| Publication Start Year | 2013 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Other charges | Visit website |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 18 |
| Article Processing Charges | USD 2885 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY-NC, CC BY, CC BY-NC-ND |
| OA statement | Visit website |
Planning to publish in Journal for ImmunoTherapy of Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (Journal for Immuno Therapy of Cancer (2019) 7 (40) DOI: 10.1186/s40425-018-0492-x)
- 6 Mar 19
- Journal for ImmunoTherapy of Cancer
-
Full paper
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
- 4 Nov 16
- Journal for immunotherapy of cancer
-
Full paper
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
- 18 Oct 16
- Journal for immunotherapy of cancer
-
Full paper
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
- 18 Oct 16
- Journal for immunotherapy of cancer
-
Full paper
Acute visual loss after ipilimumab treatment for metastatic melanoma.
- 18 Oct 16
- Journal for immunotherapy of cancer
-
Full paper
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.
- 18 Oct 16
- Journal for immunotherapy of cancer
Scite analysis
Powered by scite_
4.6k articles received 96.1k citations see all
- 3,091 Supporting
- 91,568 Mentioning
- 343 Contrasting
Editorial notices
- 1 Retractions
- 0 Withdrawals
- 214 Corrections
- 184 Errata
- 0 Expression of Concern
FAQs
How long has Journal for ImmunoTherapy of Cancer been actively publishing?
Journal for ImmunoTherapy of Cancer has been in operation since 2013 till date.
What is the publishing frequency of Journal for ImmunoTherapy of Cancer ?
Journal for ImmunoTherapy of Cancer published with a Continuous publication frequency.
How many articles did Journal for ImmunoTherapy of Cancer publish last years ?
In 2023, Journal for ImmunoTherapy of Cancer published articles.
What is the eISSN & pISSN for Journal for ImmunoTherapy of Cancer ?
For Journal for ImmunoTherapy of Cancer,eISSN is 2051-1426 and pISSN is2051-1426.
What is Citescore for Journal for ImmunoTherapy of Cancer ?
Citescore for Journal for ImmunoTherapy of Cancer is 14.3.
What is SNIP score for Journal for ImmunoTherapy of Cancer ?
SNIP score for Journal for ImmunoTherapy of Cancer is 2.23.
What is the SJR for Journal for ImmunoTherapy of Cancer ?
SJR for Journal for ImmunoTherapy of Cancer is Q1.
Who is the publisher of Journal for ImmunoTherapy of Cancer ?
BMJ PUBLISHING GROUP is the publisher of Journal for ImmunoTherapy of Cancer.